Clinical trials: Shy-Drager Syndrome
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
- Trial name
- NCT07617012
- Testing
- XS411CN Cell Injection
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Hypertension, Pure Autonomic Failure
The Role of Endothelin in the Supine Hypertension of Autonomic Failure
The purpose of this study is to test the hypothesis that endothelin plays a role in the pathogenesis of supine hypertension in pure autonomic failure by increasing vascular resistance.
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT01119417
- Testing
- BQ123, Saline
- Where
- United States
- Sponsor
- Vanderbilt University
Multiple System Atrophy
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Multiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia.
- Trial name
- NCT05167721
- Testing
- Autologous Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Mayo Clinic
Multiple System Atrophy
A Futility Trial of Sirolimus in Multiple System Atrophy
Single-center, randomized, placebo-controlled, phase-II, futility clinical trial to determine if oral sirolimus is of sufficient promise to slow disease progression in MSA, prior to embarking on a large-scale and costly phase III…
- Trial name
- NCT03589976
- Testing
- Sirolimus 2 MG
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- NYU Langone Health
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy
The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing…
- Trial name
- NCT06890390
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study.
- Trial name
- SPRITE (NCT06765733)
- Testing
- Aleeto
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Post Acute COVID-19 Syndrome, Long COVID
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent
- Trial name
- DSBLongCOVID (NCT05638620)
- Testing
- stellate ganglion block with 0.5% bupivacaine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonathann Kuo, MD
Multiple System Atrophy
Synapse Alterations in MSA Patients
Synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (MSA) remains limited.
- Trial name
- NCT06221644
- Testing
- [18F]SynVesT-1 PET/CT
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Xiangya Hospital of Central South University
Parkinson Disease, Multiple System Atrophy
Synuclein-One Study
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
- Trial name
- NCT04700722
- Testing
- Skin Biopsy
- Where
- 23 sites in United States
- Volunteers
- 428 people
- Sponsor
- CND Life Sciences
Multiple System Atrophy
Natural History and Disease Progression Biomarkers of Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction.
- Trial name
- ASPIRE-MSA (NCT04229173)
- Testing
- MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional)
- Where
- 10 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
- Trial name
- NCT07197866
- Testing
- TEV-56286
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 200 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Multiple System Atrophy, Autonomic Failure
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
- Conditions
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension, Bladder, Neurogenic
- Trial name
- STAG-MSA (NCT03593512)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Oxford
Multiple System Atrophy
Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that leads to major disability, forcing patients and caregivers to adapt their environment and lifestyle.
- Trial name
- ETP@MS (NCT05819957)
- Testing
- Therapeutic Education Program (TEP)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Parkinson Disease, Multiple System Atrophy
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime…
- Conditions
- Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure
- Trial name
- NCT02640339
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson's Disease, Parkinsonism
Modifiable Variables in Parkinsonism (MVP)
We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD…
- Conditions
- Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT02194816
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Bastyr University
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD
MSA - Multiple System Atrophy, MSA
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism…
- Trial name
- NCT07465198
- Testing
- MSCs
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Biocells Medical
Multiple System Atrophy
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare and aggressive neurodegenerative disorder characterized by a combination of motor impairments, autonomic dysfunction, and cerebellar ataxia, with no currently available disease-modifying…
- Trial name
- NCT07036939
- Testing
- Immediate LVA, Delayed LVA
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Multiple System Atrophy (MSA)
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA.
- Trial name
- NCT05923866
- Testing
- ONO-2808
- Where
- 35 sites in United States, Japan
- Volunteers
- 92 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
OBESITY, HYPERTENSION
The Autonomic Nervous System and Obesity
In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I.e., we take in more energy, in the form of food, than we expend, e.g., by exercise.
- Conditions
- OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
- Trial name
- NCT00179023
- Testing
- Trimethaphan, Pseudoephedrine
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University